ABVC BioPharma Files 8-K on Financials

TL;DR

ABVC BioPharma dropped an 8-K on financials, check it out.

AI Summary

ABVC BioPharma, Inc. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial status. The company, incorporated in Nevada, is based in Fremont, California.

Why It Matters

This filing provides investors with crucial updates on ABVC BioPharma's financial health and operational performance, which can influence investment decisions.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant financial or operational news that may impact a company's stock price, requiring careful review.

Key Players & Entities

• ABVC BIOPHARMA, INC. (company) — Registrant
• August 15, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 44370 Old Warm Springs Blvd. Fremont, CA 94538 (address) — Business address

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar

Filing Documents

• ea0211475-8k_abvc.htm (8-K) — 25KB
• ea021147501ex99-1_abvc.htm (EX-99.1) — 30KB
• ex99-1_001.jpg (GRAPHIC) — 2KB
• 0001213900-24-069338.txt ( ) — 236KB
• abvc-20240815.xsd (EX-101.SCH) — 3KB
• abvc-20240815_lab.xml (EX-101.LAB) — 33KB
• abvc-20240815_pre.xml (EX-101.PRE) — 22KB
• ea0211475-8k_abvc_htm.xml (XML) — 3KB

02 Results of Operations and Financial

Item 2.02 Results of Operations and Financial Condition. On August 15, 2024, ABVC BioPharma, Inc. (the " Company ") issued a press release announcing its financial results for the second quarter ended June 30, 2024, which were disclosed in the Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 14, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information reported under this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Neither this Current Report on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company's securities in any state in which such an offer, solicitation or sale would be unlawful. The securities mentioned herein have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws.

01 Exhibits

Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File, formatted in Inline XBRL 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. August 15, 2024 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR